# **Trustees’ Annual Report and Financial Statements** 2023/24 

**Our R.A.C.E to overcome the UK’s head & neck cancer crisis** 



## **Contents** 

**Overview 3 Strategic 11** Research **13** Awareness **22** Collaboration **26** Engagement **31 Fueling our mission 36 Financial statements 39** 


2 



## **Thank** 

## **you** 

We want to thank everyone who has been a part of this challenging but impactful year. 

To our wonderful team and volunteers - your dedication shines through in everything you do. We see the difference you make every day, and we couldn't be prouder to have you with us. 

Our brilliant researchers and healthcare professionals continue to push boundaries, working tirelessly to transform head and neck cancer care across the UK. Your groundbreaking work gives hope to so many people affected by this disease. 

And to everyone who has shared their head and neck cancer journey with us - you are the reason we do what we do. Your strength and stories guide our work and fuel our determination to make things better. 

We've taken big steps forward this year, but there's still so much more to do. 

With your support, we'll keep pushing forward until we overcome head and neck cancer's biggest challenges and improve the lives of everyone affected by this disease. 

Thank you for standing with us. 


3 



## in numbers **Our year** 

A Year of Impact 

**1 Merger** 



**79** 

HNCF and Oracle Cancer Trust became Oracle Head & Neck Cancer UK 


**2** 

National campaigns launched 

**8** Peter Rhys-Evans Scholarships awarded 


**30** 

Patients & carers steering our work as part of Oracle Voices, our Patient & Public Advisory Group (PPIE) 

MPs and key policymakers briefed 

**175** Head & neck cancer oncologists, surgeons & allied specialists engaged. **£198,000+** Invested in research* **£498,899** Fundraising income 

Head & neck cancer oncologists, surgeons & allied specialists engaged. 

4 

*This represents research funding cash allocation, majority of accounting impact accrued in prior years. 



## **Introduction** 

We are the UK's largest charity focusing on head and neck cancers, working to improve lives through research, awareness and support. Our mission drives everything we do - from funding awareness campaigns and innovative research to providing comprehensive support for patients and their families. 

Prevention and early detection are at the core of our approach. Through pioneering initiatives like Sign Away Cancer and HeadNeckCheck, alongside partnerships with dental and GP practices and community organisations, we're making head and neck cancer awareness part of everyday healthcare. Early detection saves lives, and knowledge makes all the difference to patient outcomes. 

Research is at the heart of creating change. We fund pioneering projects that push boundaries in understanding, treatment and outcomes. Among our diverse research portfolio this year, one example is the completion of a 3-year multi-centre HPV study across seven UK hospitals led by Associate Professor Elizabeth Marsh from the University of Derby. 

This and other research projects are helping build our understanding of how these cancers develop and affect different groups, leading to better prevention strategies and more personalised treatments. 

Supporting patients and their families throughout their head and neck cancer journey remains fundamental to our work. Through initiatives such as our Oracle Voices patient and carer advisory group, who lead our PPIE activities (patient and public involvement and engagement), we are working to break down barriers to care and ensure every voice is heard - from diagnosis through treatment and beyond. 

Working together creates a bigger impact. By bringing together healthcare professionals, researchers, policymakers, patients, carers and communities, we are building partnerships to tackle healthcare inequalities and champion prevention and early detection. The launch of work towards a comprehensive national audit feasibility project, supported by multiple partners across the head and neck cancer community, demonstrates how collaboration drives meaningful change. 

## **Preventing Cancer Beats Curing it** 

Through Research, Awareness, Collaboration & Engagement with people affected by head & neck cancer, we are committed to creating lasting change. 

Together with our supporters, we are building a future where these cancers are better understood, more effectively treated, and ultimately prevented. 


-Professor Anson MacKay, Oracle Voices Co-Chair 

5 



## **Our Mission** 

Improve Head and Neck Cancer patient quality of life and outcomes in the UK. **Our Vision** 

A future where head and neck cancer rates decline, symptoms are widely recognised, diagnoses come early, and healthcare teams have the resources to provide excellent care. Where the UK leads in outcomes, inequalities are eliminated, and a strong community of patients, carers, and healthcare professionals ensures no one faces their journey alone. 

6 



**7** 

## **Kelly’s Story** 


**Kelly Watson knew something wasn't right when she started choking on food. But getting answers would prove to be one of her biggest battles.** 

## **Fighting for Answers** 

What started with swollen glands and difficulty swallowing in August 2023 led to multiple GP appointments and frustrating delays. Despite her instincts telling her something was seriously wrong, Kelly was initially told she just had a swollen tonsil. 

Despite presenting with clear symptoms, including choking on food and visible lumps, Kelly faced multiple hurdles, including cancelled appointments, delayed test results and an initial misdiagnosis as infection. 


**I felt like I had to fight to stay alive.** 

At just 43, this Yorkshire mum faced a threemonth journey from her first symptoms to starting treatment. "I felt like I had to fight to stay alive. To fight and fight to get the care I needed." 

"While I was waiting for treatment, I felt the cancer was just being left to grow... It was really scary. It would have helped so much to be treated on time." 

## **Patient Story** 

Despite the difficulties, Kelly found crucial support through our Oracle Voices volunteers, Dani and Hazel, who connected her with others who understood her journey. 

Our partnership with Young Tongues charity provided additional age-specific support that proved invaluable. 


**I want future patients to get good care, no matter who they are or where they are.** 

**At the moment, it's a postcode lottery. And if we don't speak up, nothing will change.** 

Kelly's experience reinforces why our work is so vital. From our primary healthcare #HeadNeckCheck awareness campaign to funding research, to providing support networks and advocating for better care standards across the UK. 

Her story drives us to keep pushing for earlier diagnosis, consistent care, and better outcomes for everyone affected by head and neck cancer. 


7 




## **The 2023/2024 fiscal year has marked a period of meaningful progress and strategic development for Oracle Head & Neck Cancer UK.** 

While navigating the ongoing economic challenges and aftermath of recent years' disruptions, we have focused on strengthening our foundation through improved data management, enhanced systems, and a more robust approach to fundraising - all vital steps in better delivering our charitable objectives. 

A landmark achievement this year was our merger with the Head & Neck Cancer Foundation (HNCF). We are deeply grateful to HNCF's founders, Professor Mark McGurk and Sir Frederick Hervey-Bathurst, for entrusting us with their legacy and for their continued commitment to our shared mission. 

## Message from our **Chair** 

Moving forward, we remain committed to addressing key challenges, particularly in fundraising and expanding our reach, to ensure we can make an even more substantial difference. 

Their vision and dedication remain integral to our future work. As part of this strategic union, we were delighted to welcome Michelle Vickers, HNCF's former CEO, who has taken on the crucial role of Chief Awareness Officer, working alongside our Chief Executive, Tamara Kahn, to strengthen our combined impact and reach. 

On behalf of the trustees and team, I express my sincere thanks for your continued support. Together, we are working towards a future where head and neck cancers are better understood, diagnosed, and treated. 

Head and neck cancers remain a significant healthcare challenge, with their impact often understated. As the UK's largest head and neck cancer charity, we maintain our unwavering dedication to raising awareness, supporting patients, and driving research to improve outcomes for those affected by these cancers. This commitment underpins all our work, from community engagement to healthcare professional collaboration. 

## **Keith Jones** 


The board continues to evolve, bringing together diverse expertise spanning clinical practice, academic research, financial management, and strategic planning. This breadth of experience has proved invaluable in shaping our strategic direction and ensuring robust governance as our organisation expands. 

**Chair of Trustees** 

Our strategy is showing clear signs of success. Our collaborations, research projects, and patient-focused campaigns are effectively aligned with our objective of creating meaningful change in head and neck cancer care. 


8 




**As I reflect on 2023/24, I'm struck by both the challenges we've faced and the remarkable transformation we have achieved at Oracle Head & Neck Cancer UK. This was a year that tested our resilience but also reinforced the critical importance of our mission.** 

The head and neck cancer crisis in the UK continues to deepen. Every day, we see the impact of growing incidence, late diagnosis, growing inequalities in care, and the devastating effects these cancers have on people's lives. 

Through Oracle Voices, our patient and public involvement group, we have heard firsthand how these challenges affect real people - their struggles with diagnosis, treatment, and life-changing after-effects. 

We needed to be bolder, more innovative, and more determined in our response. 

## Message from our **Chief Executive** 

Throughout these challenges, I have been continually inspired by the dedication of everyone in our community - from the healthcare professionals working overtime to the researchers pioneering new treatments and the often-unsung heroes: community nurses, late effects specialists, allied healthcare teams, and school vaccination teams. Most inspiring of all are the patients and families who, despite their own struggles, share their stories to help others. 

This drove a fundamental transformation in how we work. We expanded our research mandate wider than early research grants to encompass social determinants of health and crucial data initiatives. 

We launched major awareness campaigns – Sign Away Cancer tackling HPV awareness and vaccination, and HeadNeckCheck.com empowering people to spot early symptoms. Working alongside key partners, including BAHNO and the Head and Neck Cancer UK Coalition, we helped launch a vital national audit feasibility study - the first comprehensive review of these cancers in over a decade. 

While we faced significant challenges and there are more ahead, I am proud of how we have emerged stronger from this pivotal year. Our projects, partnerships, and newly unified organisation demonstrate that even in the toughest times, we can drive positive change. 

We have had to reimagine our approach to fundraising and operations, finding creative ways to maximise our impact despite limited resources. This meant difficult decisions and countless late nights, but it also sparked innovation in how we work and deliver change. 

As we look ahead, we remain more committed than ever to our vision of better outcomes for everyone affected by head and neck cancer in the UK. Thank you to everyone who has supported us through this transformative year. 

This year of transformation culminated in our merger with the Head & Neck Cancer Foundation in April 2024. This union wasn't just about organisational efficiency - it was about creating the stronger foundation needed to tackle the growing crisis in head and neck cancer care. 

Your commitment makes our work possible, and together, we will continue to make a difference. 


By bringing together Oracle's research excellence with HNCF's community engagement strengths, we have built an organisation better equipped to drive meaningful change. 

**Tamara Kahn Chief Executive Officer** 


9 



## **Head & Neck Cancer** 

**Head and neck cancers have reached a critical point in the UK's healthcare landscape. Now ranking amongst the top-5 cancers in men and top-10 overall, these complex diseases present unique challenges in both diagnosis and treatment.** 

With 14 distinct areas where tumours can develop in the head and neck region, each case demands specialised expertise and careful assessment. 

## **A Growing Healthcare Crisis** 

## **Prevention: A Widening Gap** 

Three key preventive measures are falling short: 

HPV vaccination rates lag behind comparable nations 

Millions lack access to NHS dental care - a crucial early-warning system for these cancers. While traditional cigarette smoking rates are gradually declining there is still concerning cancer risk from other uses of tobacco 

## **Rising Numbers, Growing Concern** 

The statistics paint a stark picture. Every decade sees a 30% increase in cases, with annual diagnoses now reaching 17,000, including thyroid cancers. This sustained rise shows no signs of slowing, putting unprecedented pressure on our healthcare system. 

## **Treatment Delays and Survival Crisis** 

Our NHS faces a troubling reality: head and neck cancer patients endure the longest waiting times of any cancer type. The figures are alarming: 

- Over half of patients wait beyond the crucial 62-day target for treatment to begin Many face delays of several months before starting vital treatment These waiting times are consistently the worst among all cancer types The backlog continues to grow despite intervention attempts 

The impact on survival is devastating. While other cancers have seen improved survival rates over recent decades, head and neck cancer outcomes remain stubbornly poor: 

- Late diagnosis occurs in over 50% of cases When diagnosed late, survival rates drop dramatically Treatment becomes more complex and costly Unlike many other cancers, survival rates have shown minimal improvement over the past decade 

This creates a vicious cycle: longer waits lead to more advanced cases, requiring more intensive treatment, which in turn puts more pressure on already stretched resources. 

## **Infrastructure and Resource Gaps** 

The UK lags behind its European counterparts in crucial areas: 

Critical shortages of treatment machines Insufficient specialist staff Limited treatment capacity 




**Over 50% wait beyond 62-day target** 

**Double cancer rates in deprived communities** 

**Receives less than 3% of research funding** 

## **The Human Cost** 

The impact of head and neck cancer extends far beyond medical statistics. Late diagnosis forces patients through more aggressive treatments, leading to: 

Severe challenges with speaking, eating and swallowing Higher rates of mental health issues compared to other cancers Devastating financial burden on both patients and the NHS 

## **Research-Funding Disconnect** 

Despite representing a growing health crisis, head and neck cancers receive less than 3% of UK cancer research funding - amongst the lowest for any cancer type. This disparity between need and investment hampers our ability to improve outcomes and develop new treatments. 

## **Call to Action** 

**This crisis demands immediate attention and action. Without significant changes in prevention, diagnosis, treatment resources and research funding, we risk failing an increasing number of patients who deserve better care and better outcomes.** 



**Over 50% of cases 17,000 annual diagnosed late diagnoses and rising** 

**30% increase every decade** 

10 



## **A Powerful New Chapter** 

Tamara Kahn CEO and Michelle Vickers CAO photo 

## **In May 2024, we achieved a momentous milestone and created something extraordinary - the merger of Oracle Cancer Trust and the Head & Neck Cancer Foundation into Oracle Head & Neck Cancer UK, complete with a powerful new identity to match our ambitious vision.** 

This wasn't just about bringing two organisations together - it was about creating a stronger, more visible force in the fight against head and neck cancer. The Head & Neck Cancer Foundation, founded by the visionary Professor Mark McGurk and Sir Frederick Hervey-Bathurst, brought with it an incredible legacy of innovation and dedication to patient care. We are honoured that they have entrusted us with this legacy and are grateful for their continued guidance and support as we move forward together. 

By combining our expertise, resources and shared passion, we've built something special. While our commitment to groundbreaking research remains unwavering, we recognised that awareness could save lives too. That's why education and early detection became central to our new strategy. 

This wasn't just about creating a new logo; it was about making our mission more visible and making an impact. 

We were thrilled to welcome Michelle Vickers, former CEO of HNCF, as our Chief Awareness Officer. Michelle's passion for spreading awareness and her talent for connecting with people has already helped us reach more communities than ever before. 

From our redesigned website to our aligned communications, everything we do now works harder to support our community and spread our message. By pooling our medical networks, research programmes and awareness campaigns under one strong identity, we're now better equipped than ever to make a real difference in the R.A.C.E to overcome the head and neck cancer crisis in the UK. 

Together, we're louder, stronger and more determined than ever - with a brand that reflects our bold ambitions for the future. 


L-R: Tamara Kahn, CEO and Michelle Vickers Chief Awareness Officer 




11 



the **R.A.C.E Leading** to Overcome Head & Neack Cancer Crisis 

**Every day, we witness both the challenges patients face and the incredible breakthroughs that bring hope.** Our **R.A.C.E** framework isn't just an acronym - it's the heartbeat of everything we do, pushing us forward in our mission to advance research, care, and outcomes for everyone affected by head and neck cancer. 





## **R** esearch 

## **A** wareness **C** ollaboration 

**E** ngagement 


12 



## **R** esearch 

**Research isn't just about labs and clinical trials. It's about Sarah, who can still sing to her grandchildren thanks to voice-preserving surgery developed through research we funded. It's about giving patients better options, kinder treatments, and more tomorrows.** 

In 2023-24 we expanded our research into three vital areas: 

**Funding innovative research projects to advance diagnosis and treatment:** Working with leading institutions and clinicians, our grants help turn promising ideas into better ways to diagnose, treat and care for patients. 

## **Exploring how head and neck cancers affect different** 

**communities:** Through research into real-world experiences and barriers to care, we're developing better ways to help patients and families throughout their cancer journey. 


**More than £198k invested in research** 

**Funded 7 Innovative Medical Research Programmes** 

**Millions of follow-on funding secured** 

## **Improving data on diagnosis patterns, treatment approaches,** 

**and outcomes:** By collecting and analysing comprehensive data, we can make informed recommendations around best practices, areas needing improvement, and healthcare policy improvements. 


13 




**When we fund research, we want to make sure it makes a real difference to people's lives. That's why we work to the high standards set by the Association of Medical Research Charities (AMRC), with an independent research committee carefully overseeing all our projects.** 


14 




**----- Start of picture text -----**<br>
Dr Elizabeth Marsh<br>**----- End of picture text -----**<br>


## **Researcher Spotlight** 

## **Pioneering HPV Research** 

## Dr Elizabeth Marsh of The University of Derby 

The team examined lifestyle factors, though no significant difference was found between men and women in HPV detection rates. 

**In 2023/24, Oracle funded groundbreaking research across six hospitals in the Midlands and North of the UK to better understand how HPV affects throat cancer development.** 

This research helps to build a greater understanding of how HPV affects healthy tissue and why certain groups might be more vulnerable to HPV-related cancers. It represents an important step in Oracle's mission to improve outcomes for everyone affected by head and neck cancer. 

This vital work, led by Dr Elizabeth Marsh of the University of Derby, with PHD candidate Mary-Anne Freckleton, helps understand why these cancers are becoming more common and how they might be prevented. 


The research team studied 118 participants who were having routine tonsil surgery. They found that about 10% of healthy adults had HPV in their tonsils. 

**Fundamental research like our project is critical to unpick how HPV causes head and neck cancer. Understanding what the virus is doing in early infections will enable better treatments and patient outcomes down the line.** 

All HPV types found were considered high-risk, with HPV18 being the most common. The team discovered that when HPV was present in one tonsil, it was usually present in both, though it varied across different parts of the same tissue. 

The research revealed important differences in how HPV affects tissue. In tonsils with HPV, the team found: 

**With such limited funding for head and neck cancer studies, despite head and neck cancer being the 8th most common cancer, Oracle project grants are essential to progress research and have impact  in this field.** 

Increased proteins involved in immune response Decreased proteins involved in cell death and genomic stability 

In men specifically, there was a significant decrease in proteins involved in RNA processing and protein production 

Dr Elizabeth Marsh 

Mary-Anne Freckleton1*, Rebecca Mallender1,2*, Thomas A. Illingworth1, Laurice V. Fretwell1, David J. Boocock3, Clare Coveney3, Gill L. Knight4, Amandeep S. Mann5, Thomas Hatfield5, Raguwinder S. Sahota1,5,6,7, Elizabeth K. Marsh1ǂ 1 University of Derby, Derby, UK 

2 HistologiX Ltd, Nottingham, UK 

3 Nottingham Trent University, Nottingham, UK 

4 University of Wolverhampton, Wolverhampton, UK 

- 5 University Hospitals of Derby and Burton, Derby, UK 

- 6 University of Leicester, Leicester, UK 

- 7 University of Nottingham, Nottingham, UK 

## **Looking Ahead** 

This research represents Oracle's significant investment in understanding and preventing HPVrelated throat cancers, bringing the charity closer to its goal of better outcomes for everyone affected by head and neck cancer. 

Future research will focus on expanding the understanding of HPV-related cancers, exploring new diagnostic techniques, and identifying effective prevention strategies. 

This work will help to build a greater understanding of how HPV affects healthy tissue and could lead to better ways of identifying those at risk. 


- Equal contributors to the work ǂ Corresponding author e.marsh@derby.ac.uk 

15 



## **BREAKTHROUGH RESEARCH** 

## Making Immunotherapy 

## Work for More Patients 

## **What is Immunotherapy?** 

Immunotherapy is a type of cancer treatment that helps the patient's own immune system fight cancer. Think of it as 'waking up' the body's natural defenses to recognise and attack cancer cells. 

## **Why It Matters in Head and Neck Cancer:** 

Radiotherapy alone doesn't always achieve long-term tumour control Many patients experience severe long-term side effects from current treatments 

Some cancers are harder to treat with standard approaches 


## **The Challenge** 


**----- Start of picture text -----**<br>
Up to Only<br>1000s<br>60%  15-20%<br>of head and neck cancer of patients respond to face this devastating<br>patients see their  current immunotherapy reality each year<br>cancer return treatments<br>**----- End of picture text -----**<br>


## **Our Response** 

Through the amazing support of a key donor, Oracle was able to launch a call for grant applications in support of groundbreaking treatment innovations. Dr Emmanuel Christian Patin from the Institute of Cancer Research, under the supervision of Prof Kevin Harrington, received multi-year funding for research around combination therapy using immunotherapy for head & neck cancers. 

By combining radiotherapy with targeted drugs and immunotherapy, the team has discovered new ways to help the body's immune system fight cancer more effectively. This research aims to tackle both HPV-positive and HPV-negative tumors, with the goal of improving treatment outcomes while reducing side effects. 

_This vital work was also made possible through funding from DPS Limited and has led to the development of new research models now used by scientists worldwide._ 

16 




## **Researcher Spotlight** 

Dr Emmanuel Christian Patin of The Institute of Cancer Research 

**Between 2020-2023, with our support, Dr Patin led groundbreaking research that could transform how we treat head and neck cancer. The research team pioneered an innovative approach combining radiotherapy with targeted drugs and immunotherapy, work that has now progressed to clinical trials.** 

**Developed new research models now used by scientists worldwide** 

**Advanced to Phase II clinical trials, bringing hope closer to patients** 

**Created specialist tools to study immune responses** 

**Mentored the next generation of cancer researchers** 

## **The Impact** 

**Secured £2.3 million Cancer Research UK Programme Grant** 

**Created new approaches combining radiotherapy with targeted drugs and immunotherapy** 

**Progressed to clinical trials** 

**Developed methods that could reduce treatment side effects** 

## **Lasting Change** 

**This project epitomises how our support can create lasting change.** 

**By fostering high-risk, highreward research, we have contributed to discoveries that have the potential to improve outcomes for patients with head and neck cancer worldwide.** 

17 




## **UNDERSTANDING HEAD & NECK CANCER** 

## National Audit Feasibility Study 

**Unlike most other top 10 cancers in the UK, head and neck cancers have lacked a comprehensive national audit for over a decade.** 

This significant gap means we have been missing crucial data to understand who is developing these cancers, where they're being diagnosed, how they're being treated and how the outcomes differ. Without this robust data infrastructure, it is difficult to understand treatment effectiveness, identify best practices, and address disparities in care access. 

Cancer audits are also vital tools that help identify areas for improvement, share best practices, and monitor the impact of early diagnosis initiatives. This £270,000 two-year feasibility study, led by Dr. Thomas Cowling at the London School of Hygiene and Tropical Medicine, aims to establish a national picture of how head and neck cancer is diagnosed and treated. 

## **Driving Progress Through Innovation** 

This year, Oracle has played a pivotal role in bringing together key organisations to launch this crucial initiative, working closely with the Head and Neck Cancer UK Coalition and the British Association of Head and Neck Oncology (BAHNO) to unite the head and neck cancer community behind this vital project. 

Alongside our £40,000 co-funding commitment, we've helped coordinate support from leading organisations including Oracle, BAHNO, GetaHead, ENTUK, National Association of Laryngectomee Clubs, Young Tongues, BAHNON, HaNC Liverpool, BAOMS, RD-UK, North West Cancer Research. This £270,000 two-year feasibility study, led by Dr. Thomas Cowling at the London School of Hygiene and Tropical Medicine, aims to establish a first comprehensive national picture of how head and neck cancer is diagnosed and treated. 

## **The study will:** 

Develop and evaluate key performance indicators for diagnosis, treatment, and outcomes 

**This process is long overdue and absolutely critical. As clinicians, we need this data to drive best practices, reduce treatment disparities, define research strategies and ultimately save lives.** 

Assess variations in care across regions and patient groups Identify priority areas for improvement Explore expanding research to less common head and neck cancer sites 

_Professor Vin Paleri of The Royal Marsden Hospitals_ 


18 



**By understanding and working with our communities, we can advance care and improve outcomes for everyone affected by head and neck cancer.** 

19 



## **Co-Creating Health** 

## **Awareness:**[A Community-Led Approach to] Cancer Prevention 

## **A groundbreaking initiative has demonstrated the power of genuine community collaboration in understanding and addressing head and neck cancer awareness.** 


The project, co-led by Dr Oladejo Olaleye (Consultant Head & Neck / Robotic Surgeon, University Hospitals of Leicester NHS Trust) and Dr Gianina Ioana-Postavaru (Psychologist, University of Leicester), partnered with seven community groups to identify current awareness levels, understand barriers to early diagnosis, and co-develop effective prevention strategies. 

Working alongside Dr Naina Patel (PPIE Lead), Ms Aleksandra Jakubowska (Doctoral researcher), and the Oracle Head & Neck Cancer UK team, the project engaged with diverse communities to understand their unique perspectives and challenges. 

Through this collaborative approach, the team identified key barriers to prevention and early diagnosis, leading to the co-creation of more culturally responsive and effective awareness campaigns. 


Oladejo Olaleye1, Gianina Ioana-Postavaru2, Naina Patel3, Aleksandra Jakubowska2, Tamara Kahn4 

. 

## **More Than Words** 

One of our most significant findings was the complex relationship between communities and healthcare services. While there is strong trust in GPs, postpandemic access challenges have created new barriers. Community pharmacists have emerged as vital bridges, often serving as the first point of contact for health concerns. This insight could help to develop more effective pathways for early cancer detection. 

**We don't just want information handed to us. We want to be part of creating the solution.** 


**----- Start of picture text -----**<br>
Participant from the drama group<br>**----- End of picture text -----**<br>


## **Looking Ahead** 

The success of this initiative has shown that community co-production is not just beneficial – it's essential. Community participants have actively invited further engagement, demonstrating an appetite for health awareness campaigns that reflect their experiences and values. 

Through collaborative work with temples, community centers, and local cultural organisations, we're building a foundation for lasting change in how healthcare messages reach and resonate with diverse communities. 

This isn't just about delivering information – it's about creating partnerships that will improve health outcomes for years to come. 


20 

1University Hospitals of Leicester NHS Trust & UHL Head and Neck Cancer Research Institute 2School of Psychology and Vision Sciences, University of Leicester 

3NIHR Research Support Service, University of Leicester 

4Oracle Cancer Trust (Oracle Head and Neck Cancer UK) 



## **LOOKING AHEAD** 

**Our Plans to Transform Head and Neck Cancer Research** 

**Research holds the key to better treatments and care. That's why we're changing how we fund research to make sure every penny counts towards helping patients. Here's how we're planning to make an even bigger difference in 2024-25.** 

## **Working Together to Fund Major Research** 

We're partnering with other organisations to fund bigger research projects. By sharing costs with our Partners we can tackle major challenges in head and neck cancer care. 

## **Small Grants, Big Ideas** 

Not all great ideas need big budgets. We're launching a new scheme to fund smaller projects. This will help medical professionals develop new ways to improve care, test new ideas, and support different approaches to research. 

## **Supporting Future Research Leaders** 

We're working with the partners to support promising researchers. Together, we'll fund experts who want to find ways to reduce the long-term effects of treatment, understand why some people get better care than others and make treatment better for everyone effected by head & neck cancers. 

21 



## **A** wareness 

**Awareness saves lives - it's that simple. When Tom noticed a persistent sore throat, he remembered our #HEADNECKCHECK campaign, went to his GP practice linking his symptom with what he knew about head and neck cancers. This led to an early diagnosis.** 

**That's why we're out there, making noise, starting conversations, and making sure everyone knows the signs, symptoms and risk factors that could save their life.** 

Throughout 2023-24, we continued to raise awareness of head and neck cancers through participation in key campaigns and initiatives. 

Our engagement across multiple awareness days and events has strengthened our key objective to educate the public whilst supporting those affected by these diseases. 


**47,000 people engaged** 

**More than 500 people in our support group** 

**Over 1000 head & neck check guides distributed** 


22 



**In the UK, over 47 people are diagnosed with head and neck cancer every day.** 

23 



## **YOUR LIFE IN YOUR HANDS** 

## The #HeadNeckCheck Campaign 

Knowing your own body can save your life. That's why we launched **#HeadNeckCheck** in early 2024, turning everyday moments into opportunities for potentially life-saving self-checks. 

**Most of us brush our teeth and check our faces in the mirror daily, but how many of us really know what to look for when it comes to signs of head and neck cancer?** 

## **Our campaign aims to change this by making self-checks simple, quick and part of everyday life.** 


Working with healthcare professionals, we created a straightforward video guide that took the mystery out of self-examination. No medical jargon - just clear, practical steps showing people how to check their mouth, throat and neck. 

Whether it's spotting unusual lumps, persistent sore throats that won't go away, or changes in swallowing, knowing what to look for makes all the difference. 

We have sent 100s of flyers to GP practices across the country and we have started to run primary healthcare workshops with GPs. Our goal is to raise awareness amongst both the patients in the waiting rooms and the GPs seeing them. 

We also partnered with dental practices across the UK to spread our message: your dentist isn't just checking your teeth - they're a crucial first line of defence in spotting early signs of cancer. 

By combining regular dental check-ups with home self-checks, we're helping people take control of their health. 


24 



## **LOOKING AHEAD** 

## Making our voices heared and our impact felt 


**Awareness is vital for early diagnosis and saving lives. That's why we're transforming how we share the signs and symptoms of head and neck cancer, from launching our #HeadNeckCheck early diagnosis campaign to raising understanding of HPV-related cancers among younger people. We'll also focus on helping people understand the late effects of treatment while working closely with our incredible supporters to raise vital funds. Here's how we're planning to make an even bigger difference in the year ahead.** 

## **Sign Away Cancer** 

Following the successful launch of 'Sign Away Cancer' in March 2024, we're expanding this vital campaign to reach even more families across the UK. With HPV-related cancers continuing to rise, and current vaccination rates at just 56% for girls and 53% for boys, we know we must do more. 

In the year ahead, we'll build on our partnerships with school immunisation teams and The Eve Appeal to reach communities where vaccination rates are lowest. 

We're developing new educational resources, and creating targeted campaigns to help parents understand why their signature matters so much. Our medical experts will continue to share clear, honest information about HPV and cancer prevention. 

Working closely with local health teams and other cancer charities, we'll roll out an enhanced schools programme, focusing particularly on areas with low uptake. 

We're also expanding our awareness campaign to support the catch up programmes for young people up to age 25. 

**Every signature we secure could mean one less cancer diagnosis in the future.** 

## **Late Effects** 

For many people who've been through head and neck cancer treatment, the path forward brings its own challenges. Simple things that most of us take for granted, like enjoying a meal or having a chat over coffee, can become daily hurdles. 

Many survivors find that their mouth feels constantly dry, which affects not just their enjoyment of food but also makes speaking more difficult. Imagine trying to give a presentation or catch up with friends when your mouth feels like sandpaper - this is a reality for many. 

Some people experience swelling and stiffness in their neck and face, which can limit movement and affect confidence in social situations. It's like wearing an invisible collar that restricts natural movement. 

The treatment can also affect how the body produces important hormones and maintains bone strength. These are real challenges that impact daily life, from energy levels to physical activity. 

Next year, Oracle will be working with specialists and our partners to change this landscape 

**Because surviving cancer is just the first step - living well afterwards is equally important.** 

## **Barbershop Project** 

Sometimes the most powerful conversations happen in the most everyday places. Barbers aren't just skilled professionals - they're trusted community figures who often build lasting relationships with their clients. These relationships create perfect opportunities for potentially life-saving conversations about health. 

Next year, we will be working with partners across the NHS and local councils to create a comprehensive programme that includes interactive workshops, practical training, and ongoing support for barbers who want to make a difference in their community. 

We're not turning barbers into doctors - we're empowering them with practical knowledge about head and neck cancer symptoms and risk factors that they can share naturally during their daily work. 

This initiative honours the legacy of Robert Shaw, our NHS colleague whose vision helped inspire this project. It represents exactly what Oracle stands for - finding innovative ways to reach people where they are, working with communities, and ultimately saving lives through earlier detection. 

**We're building a community of awareness, where #headneckcheck becomes as natural as looking in the mirror at the barber's.** 


25 



## **C** ollaboration 

**Collaboration is where the magic happens. By bringing together the brightest minds - researchers, doctors, patients, and other charities - we're stronger.** 


**8 community groups** 

Our approach is innovative because we don’t just share knowledge - we actively build solutions together. 

In 2023-24 we continued reaching across silos and engaging in powerful partnerships because head & neck cancer is on the rise in the UK - it won’t slow down - and nor will we in our R.A.C.E to overcome it. 

Whether it's co-developing research projects, influencing policy, or supporting patients, our partnerships amplify our impact far beyond what we could achieve alone. 

**15 coalition members driving progress together** 

**7 co-funded projects launched** 


26 



**By working together, we can drive progress and create lasting change for everyone affected by head and neck cancer.** 

27 



## **The 2024 Oracle Head & Neck Cancer Oncology Meeting - York** 

were often presenting to doctors far 

**In the constant drive to improve outcomes for head and neck cancer patients, bringing together the brightest minds in oncology remains crucial.** 

In 2024, Oracle Head & Neck Cancer UK took on the organisation of this vital event, ensuring its long-term sustainability and future impact. Thanks to the generous support of Merck, MSD, The Hobson Charity and Oracle donors, we gathered 150 of the UK's leading oncologists under one roof. From Aberdeen to Plymouth, dedicated healthcare professionals came together with one shared purpose: to transform how we treat head and neck cancer. 

What makes this gathering particularly significant is its ripple effect across the UK healthcare landscape. 

The diverse attendance, representing NHS Trusts from every corner of the country, ensures that cutting-edge research and best practices reach patients nationwide. 

The agenda brought together leading voices in head and neck oncology, fostering an environment where innovation meets practical application. 

Through structured discussions and informal networking, participants shared insights that will shape the future of patient care. 

As we continue our mission to improve outcomes for head and neck cancer patients, events like these serve as crucial catalysts for change. They remind us that in the fight against cancer, collaboration and knowledge sharing are our most powerful tools. 

Dr Robin Prestwich, Consultant Clinical Oncologist 

**The Head and Neck Cancer Oncology Conference is now a key fixture in the UK oncology calendar, providing a vital platform for multidisciplinary collaboration.** 

**The conference brings together experts from across the country, fostering networking and the exchange of best practices.** 

**In 2024, 85% of attendees rated the meeting as ‘excellent,’ and 74% reported that it would lead them to change their clinical practice.** 



28 



## **WORKING TOGETHER,** 

## Saving Lives 

**This year, we launched several vital initiatives with organisations who share our commitment to improving outcomes for people affected by head and neck cancer.** 

**In the UK, around 17,000 people are diagnosed with head and neck cancer every year** 





**Make Sense Campaign** 

In 2023, we  joined the important Make Sense Campaign. As part of this 11th annual awareness week, we focused on the three stages of prevention of head and neck cancer, underpinned by the foundational 1 for 3 rule and the 2023 motto - 3 weeks for 1 life: knowing the signs and symptoms of head and neck cancer could be lifesaving. 

**International Nurses Day** 

On 12 May 2024, we celebrated International Nurses Day by honouring the vital role of specialist head and neck cancer nurses. These professionals provide essential medical and emotional support, helping patients navigate diagnosis, treatment, and recovery. We published an article highlighting their contributions and reaffirmed our commitment to supporting these nurses, whose work improves patient outcomes and ensures the best care for those affected by head and neck cancer. 

**Mouth Cancer Action** 

In November 2023, we participated in Mouth Cancer Action Month to raise awareness of mouth cancer and its early detection. We endorsed the Mouth Cancer Charter, calling for better prevention, diagnosis, and treatment through governmentfunded campaigns, improved dental care access, enhanced professional training, and advanced diagnostic technologies. Our support reinforced our commitment to raising awareness and advocating for policies to reduce the impact of mouth cancer. 

**World Head & Neck Cancer Day** 

On 27 July 2023, we participated in World Head and Neck Cancer Day to raise awareness of the disease. Through social media, we shared educational content on risk factors and symptoms, and survivor stories like Oracle Voice’s member Jon Organ’s experience after a laryngectomy. We also partnered with University Hospitals of Derby and Burton, and University Hospital Leicester to launch a video on performing oral self-examinations. Our efforts focused on promoting early detection, prevention, and better patient outcomes. 


29 



## **United We Stand** 

The Power of Partnership 

**In a landmark move for head and neck cancer care in the UK, Oracle Head & Neck Cancer UK has joined forces with 14 other leading organisations to create something remarkable - the Head & Neck Cancer UK Coalition HNCUK.org. This isn't just another partnership; it's a transformation in how we support those affected by head and neck cancers.** 

## **Strength in Numbers** 

Imagine the impact of 14 organisations speaking with one powerful voice. From patient support groups to healthcare associations, we've brought together diverse perspectives and expertise to tackle the complex challenges of head and neck cancer care. Each member brings unique insights and resources, creating a comprehensive approach to support, education, and advocacy. 

## **Making Change Happen** 

Our coalition focuses on what matters most: improving lives. Whether it's enhancing patient support, raising awareness, advancing research, or improving treatment pathways, we're working together to create meaningful change. By aligning our messages and pooling our resources, we're achieving more than any single organisation could alone. 

## **Looking to the Future** 

This collaborative approach marks a new chapter in head and neck cancer care. Together, we're not just supporting patients and caregivers - we're transforming their experience and outcomes. From the moment of diagnosis through treatment and beyond, the coalition ensures that no one faces head and neck cancer alone. 














30 



## **E** ngagement 

**Engagement means giving power back to everyone affected by head & neck cancer.** 

From patients to carers to friends and family; it's about ensuring every voice is heard, from the newly diagnosed person seeking answers to the survivor sharing their story to help others. It's about building a community where nobody faces this experience alone. 

But engagement goes beyond just listening. It’s about action. 


**Hundreds of patients supported** 

**Over 30 active Oracle Voices members** 

It means creating spaces where people feel valued and involved in shaping the future of head & neck cancer care, research, and support. 

It’s about amplifying lived experiences to drive change, ensuring that those directly impacted have a say in the decisions that affect them. 

**10 independent research programmes contributed to by Oracle’s PPIE group** 


31 



Jono Organ, Oracle Voice 

## **Oracle Voices** 

A Growing Community Driving Impact in Head & Neck Cancer Research and Advocacy 


**----- Start of picture text -----**<br>
Hazel Turner, Oracle Voices Co-Chair<br>**----- End of picture text -----**<br>


**From June 2023 to May 2024, Oracle Voices, led by co-chairs Hazel Turner and Anson Mackay, has solidified its role as a national Patient and Public Involvement (PPI) group, uniting 25 patients and carers to shape research, awareness campaigns, and initiatives for head and neck cancers.** 

By creating a collaborative and supportive environment, the group has ensured that patient and carer perspectives are central to Oracle Head & Neck Cancer UK’s work. Over the year, Oracle Voices provided critical input to researchers, including feedback on clinical trial designs, evaluation of patient-facing materials, and contributions to projects addressing healthcare inequities. 

For example, the group collaborated with researchers and communities in Leicester on work related barriers to diagnosis in different local communities and supported studies into oxygen-enhanced radiotherapy and liquid biopsy diagnostics. Members participated in specific campaigns like Oracle’s "Sign Away Cancer" campaign, aimed at improving HPV vaccine uptake, and Merck’s carer-focused video project. These initiatives amplified the voices of patients and carers to raise awareness and inform the public. 

Key achievements include establishing Oracle Voices as a national PPI group, developing a growing and engaged membership, and making measurable contributions to research and awareness efforts. These accomplishments underscore the group’s commitment to ensuring that head and neck cancer care and research are shaped by those who live and care for others through it, making an impact that is both tangible and deeply relevant. 

**Working with Oracle, we help raise awareness of head and neck cancers. As co-leads of Oracle Voices, we aim to build on the existing foundations to further early detection and awareness.** 


**----- Start of picture text -----**<br>
Hazel Turner, Oracle Voices Co-Chair<br>**----- End of picture text -----**<br>


Hazel Turner, Oracle Voices Co-Chair 


32 



## **TRANSFORMING PATIENT CARE** 

**Our commitment to amplifying patient voices and improving care pathways has led to important developments in key areas. Through focused programmes in Leicester and East London, we're working to build stronger, more responsive support networks.** 

## **Community Impact** 

Working collaboratively with diverse community groups and healthcare providers, we have: 

- Started mapping current support services in underserved communities to identify gaps Begun developing relationships with community organisations to better understand local needs 

- Initiated conversations about improving diagnostic and treatment pathways Created platforms for community group members to share their experiences and insights 

## **Looking Ahead** 

These initial steps provide an important foundation for improving head and neck cancer care. By continuing to focus on community-centred solutions and building strong community partnerships, we aim to: 

Work with communities to co-develop campaigns that address their frustrations with them and not for them. 

Work with healthcare providers to ensure feedback around existing pathways is known and heard 

Develop practical solutions to identified challenges 

33 



## **Real Experiences, Real Support** 

## What to Expect Guidance 

**In 2023/24, we expanded our patient support resources with a comprehensive guide to the head and neck cancer journey, developed in collaboration with Oracle Voices, our Patient and Public Involvement (PPI) group.** 

This dedicated group of volunteers share their experiences and insights to help shape our work and support others on their cancer journey. 

We've also curated a collection of patient blogs offering authentic perspectives on living with head and neck cancer. These personal stories provide valuable insights and help others feel less alone in their journey. 

This peer-to-peer support has proved invaluable, with patients and families reporting feeling more informed and better prepared for what lies ahead. We continue to welcome new contributions to our blog collection and support resources, ensuring our guidance remains current and reflects diverse experiences. 

Drawing from their personal insights, we've developed detailed information to help others navigate their journey. Our resources acknowledge that every person's experience is unique while providing practical guidance on what to expect. We've also curated a collection of patient blogs, offering authentic perspectives on living with head and neck cancer. 

Understanding the diagnosis process and initial tests What to expect during different treatment pathways Managing post-treatment recovery and long-term effects Support available for family members and carers 

**Through Oracle Voices, we ensure that patient, carer and public perspectives remain at the heart of our work, helping us provide the most relevant and meaningful support to everyone affected by head and neck cancer.** 



34 



**1 1 Innovation in Action** 

## Patient-Led Diagnostic Development 

**A breakthrough in faster, gentler cancer testing is happening - and our Oracle Voices members are helping lead the way. Last year, we formed a PPI partnership with medical technology company Curenetics to explore a new quick-test for mouth cancer that could transform how quickly patients get their results.** 

This AI-enhanced diagnostic tool could transform the patient journey by combining artificial intelligence with advanced PCR technology - meaning treatment can start sooner, patients experience less physical trauma through minimally invasive testing, and the rapid results significantly reduce the anxiety of waiting for a diagnosis, revolutionizing how we detect head and neck cancer. 

**Knowing future patients might only have to wait an hour instead of weeks for results would make such a difference to their mental wellbeing.** 

_Oracle Voices member_ 

Over six months, our Oracle Voices members shared their experiences to explore how this new technology might work for real patients. They highlighted: 

**The anxiety of waiting for results The fear around having large tissue samples taken The need for clear, understandable information throughout the process** 


## **Why This Matters** 

A faster, gentler approach to diagnosis means patients can start treatment sooner, face less physical trauma from testing, and avoid the anxiety of lengthy waiting times - transforming the diagnostic journey for everyone affected by head and neck cancer. 

Our Oracle Voices members met regularly with the research team, ensuring that patient experiences and needs were at the heart of developing this new technology. This partnership shows how bringing together patient insight with medical innovation can create better solutions for everyone affected by head and neck cancer. 

## **Looking Ahead** 

This project has created a strong model for how patient voices can shape medical innovation. We're proud that our Oracle Voices members are helping build a future where getting tested for mouth cancer could be quicker, gentler, and less stressful for everyone. 


35 




## **Fueling Our Mission** 

Volunteers, Corporate Partners & Supporters 


**Our work is driven by the dedication of our volunteers, the generosity of our supporters, and the commitment of our corporate partners. Together, they help us raise awareness, fund vital research, and provide essential support for those affected by head and neck cancer.** 


## **Our People** 

Volunteers give their time, skills, and passion to support our events, fundraising, and advocacy efforts. Corporate partners strengthen our impact through sponsorships, workplace giving, and strategic collaborations. Supporters fuel our mission through donations, fundraising challenges, and spreading awareness. 

Their collective efforts enable us to reach more people, provide better support, and drive meaningful change in the **R.A.C.E** to overcome head and neck cancer. 

36 



**Together, we’re not just raising awareness; we’re transforming lives.** 

37 



## **Trekking for a Cause** 

## Conquering the Sahara Desert 

**In 2024, four remarkable individuals – Toby, Lou, Greten, and Fran – embarked on a truly extraordinary challenge to raise funds for head and neck cancer research. Their journey took them 100 kilometers across the Sahara Desert, where they raised an incredible £10,000 to support Oracle’s mission.** 

For each of our trekkers, this challenge was deeply personal. Greten was motivated by friends and loved ones who had been affected by head and neck cancer, while Lou was inspired by the strength and courage of her brother Toby, whose own battle with cancer fueled her determination. Fran, meanwhile, walked in memory of her late husband, Peter Rhys Evans, the founder and heart of Oracle Cancer Trust, whose legacy has shaped the charity for over two decades. 

**It was about raising money for a cause which had affected a number of my friends and acquaintances.** 

Gretan 

Toby, Lou, Gretan & Fran 

As they navigated the vast, daunting dunes of the Sahara, the team's spirit remained unshaken. From the isolation of the desert to the camaraderie of nights spent under the stars at desert oases, their resolve was tested and strengthened. Lou, in particular, found triumph in overcoming personal challenges, her perseverance becoming a symbol of the determination that carried the entire team through their remarkable journey. 

Guided by seasoned experts and supported by a team of camels (a fitting companion for their desert adventure), the trekkers experienced a profound sense of friendship and purpose. Between hearty meals beneath the open sky and the bustling energy of Marrakech, each moment of their journey contributed to an unforgettable experience, all while raising vital funds for head and neck cancer research. 

**This challenge goes beyond the impressive fundraising total - it shows how ordinary people can do extraordinary things to support those affected by head and neck cancer.** 

38 



# **Financial Statements** 

For the year ending 31 May 2024 


39 



## **Financial Overview** 

For the year ending 31 May 2024 

In a challenging economic environment, Oracle Head & Neck Cancer UK successfully raised nearly £500,000 in the year to 31st May 2024. This was achieved through the dedication of our staff, supporters, and volunteers, despite the broader difficulties faced by the charity sector. 

## **3. Programme Expense Ratio (Charitable Costs Ratio)** 

This ratio assesses the proportion of total expenses allocated to charitable objectives vs core operating costs, reflecting our commitment to our mission. 

We maintained a strong financial position, generating a surplus of £134,793, bringing our total funds to £316,038 at year-end. Our focus remains on financial sustainability, ensuring that the majority of our funds directly support research, awareness, collaboration, and engagement. 

Understanding and tracking key financial ratios is essential to maintaining the financial health of Oracle Head & Neck Cancer UK. These ratios provide insight into our sustainability, fundraising efficiency, and overall operational effectiveness. 

Formula: Total programme expenditure / total expenditure x 100 

- 2024 Programme Expense Ratio: 57% (£208,799 / £364,105) 

- This reflects investment in core data, technology and fundraising to support expanded delivery programmes. 

- Our target is to increase this to 75% as revenue grows, ensuring that the majority of our spending directly supports our mission. 

## **4. Current Ratio** 

## **1. Surplus or Profit Margin** 

This ratio indicates the percentage of net income relative to total income. 

Formula: Net income / total income x 100 

- Our goal is to at least break even and achieve full cost recovery for our projects and services. 

- For the year ended 31st May 2024, we generated a surplus of £134,793 (27%), strengthening our reserves for future growth. 

## **2. Fundraising Efficiency** 

This ratio measures the effectiveness of our fundraising efforts by comparing funds raised to the expenses incurred in raising those funds. 

Formula: Fundraising income / fundraising expenditure 

- A result above 1 means that for every pound spent on fundraising, we generate more than one pound in return. 

- 2024 Fundraising Efficiency Ratio: 3.2 times (£495,423 / £155,306) 

This ratio assesses our ability to meet short-term obligations with short-term assets. 

Formula: Unrestricted liquid assets / operational overheads 

- 2024 Current Ratio: 1.3 times (£200,503 / £155,306), equating to 15 months of operational overheads. 

- This provides a strong buffer to maintain financial stability. 

## **5. Reserves Ratio** 

This measures the proportion of unrestricted funds available to support operations during financial uncertainties. 

- A reserves target is typically calculated as three months’ worth of annual operating expenditure. 

- Our reserves are considered "free reserves"—unrestricted and readily available for operational support. 

With a key focus on financial metrics and strong governance in place, Oracle Head & Neck Cancer UK is well-positioned to enhance its impact, ensuring that our financial strength translates into real-world benefits for those affected by head and neck cancer. 

- This demonstrates a strong return on investment for our fundraising activities. 


40 



## **Legal & Administration** 

## **Charity Name:** 

Oracle Head & Neck Cancer UK (formally Oracle Cancer Trust) 

Mr Keith Jones (Chair) Dr Mehmet Sen Mr Gareth Thomas Mr James Robertston Prof. Gus Alusi Mr Toby Amis Mrs Ali Hansford (resigned October 2024) 

## **Trustees** 

Sir Michael Morpurgo Mr Tony Matharu 

## **Patrons** 

1142037 (England & Wales) **Charity Number** SC052790 (Scotland) **Company Number** 07125497 **Principal Address** 85 Great Portland Street, London, W1W 7LT **Registered Office** 80 Coombe Road, New Malden, KT3 4QS 

Goldwins, 75 Maygrove Road, West Hampstead, London, NW6 2EG 

## **Auditors** 

## **Statement of Trustee Responsibilities** 

03/02/2025 

**Bankers** CAF Bank Limited, 25 Kings Hill Road, West Malling, Kent, ME19 1BE Metro Bank, Southampton Row, London, WC1B 5HA **Solicitors** Dorsey & Whitney LLP, 199 Bishopsgate, London, EC2M 3UT 


41 



## **Independent auditor's report** 

## **Opinion** 

We have audited the financial statements of Oracle Head and Neck Cancer UK (formerly Oracle Cancer Trust the 'charity') for the year ended 31 May 2024 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). 

In our opinion the financial statements: 

give a true and fair view of the state of the charitable company's affairs as at 31 May 2024 and of its income and expenditure for the year then ended: 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

have been prepared in accordance with the requirements of the Companies Act 2006. 

## **Basis for Opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

## **Opinion on other matter prescribed by the Companies Act 2006** 

In our opinion, based on the work undertaken in the course of the audit: 

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the trustees' report (incorporating the directors' report) have been prepared in accordance with applicable legal requirements. 

## **Matters on which we are required to report by exception** 

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Annual Report. We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: 

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or 

- the financial statements are not in agreement with the accounting records and returns; or certain disclosures of trustees' remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit. 

42 



## **Independent auditor's report (cont.)** 

## **Responsibilities of the trustees** 

As explained more fully in the Trustees' Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so. 

## **Use of our report** 

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's members as a body, for our audit work, for this report, or for the opinions we have formed. 


## **Responsibilities of the trustees** 

[Signature] 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. 

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Anthony Epton (Senior Statutory Auditor) for and on behalf of Goldwins Limited Statutory Auditor Chartered Accountants, 

75 Maygrove Road, 

West Hampstead, 

London, 

NW6 2EG 

26 February 2025 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below. 

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following: 

- We enquired of management, which included obtaining and reviewing supporting documentation, concerning the charity's policies and procedures relating to the internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations. 

- We inspected the minutes of meetings of those charged with governance. 

- We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations. 

- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business. 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities]. This description forms part of our auditor's report. 

43 



## **Oracle Head & Neck Cancer UK Statement of Financial Activities (Incorporating the income and expenditure account) YEAR ENDED 31 MAY 2024** 

|**YEAR ENDED 31 MAY 2024**||||||
|---|---|---|---|---|---|
||**Notes**|**Restricted Funds (£)**|**Unrestricted Funds (£)**|**Total Funds 2024 (£)**|**Total Funds 2023 (£)**|
|**INCOME**||||||
|Donations and legacies|1|244,266|230,105|474,371|475,203|
|Fundraising events||-|21,052|21,052|24,071|
|Investment income|2|-|3,475|3,475|974|
|**Total Income**||**244,266**|**254,632**|**498,898**|**500,248**|
|||||||
|EXPENDITURE||||||
|Costs of raising funds||||||
|- costs of generating voluntary and<br>fundraising income|3|-|155,306|155,306|158,402|
|Expenditure on charitable activities|4|27,257|181,542|208,799|286,608|
|Total Expenditure||27,257|336,848|364,105|445,010|
|Net gains on investments||||||
|Net Income (Expenditure) for the year||217,009|(82,216)|134,793|55,238|
|Reconciliation of Funds||||||
|Total Funds brought forward (1 June 2023)||36,762|144,483|181,245|126,007|
|Transfer between funds||(138,236)|138,236|-|-|
|Total funds carried foward at May 2024||**115,535**|**200,503**|**316,038**|**181,245**|



The statement of financial activities includes all gains and losses recognised during the year. 

All income and expenditure derives from continuing activities. 

44 

The notes on pages 47 - 57 make up these financial statements 



**Oracle Head & Neck Cancer UK Balance Sheet YEAR ENDED 31 MAY 2024** 

**2024** 

**2023** 

||Notes|£|£|£|£|
|---|---|---|---|---|---|
|**FIXED ASSETS**||||||
|Tangible|9|450||734||
||||450|-|734|
|**CURRENT ASSETS**||||-||
|Debtors|10|35,000||13,496||
|Cash at bank and in hand||405,607||362,664||
|||**440,607**||**376,160**||
|**Creditors: amounts falling due**<br>**within one year**|11|125,019||180,130||
|**Net Current Assets**|||315,588||196,030|
|**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**|||316,038||196,764|
|**Creditors: amounts falling due**<br>**after one year**|12||||15,519|
|**Net Assets**|||316,038||181,245|
|**FUNDS**||||||
|Restricted Funds|13||115,535||36,762|
|Unrestricted Funds|14||200,503||144,483|
|**Total Funds**<br>**316,038**<br>**181,245**||||||



Chairman and Trustee 

These financial statements were approved by the Trustees on the …………………………. and are signed on their behalf by: Keith Jones 03/02/2025 

Company registration No: 07125497 

45 

**_____________________________** 

The notes on pages 47-57 part of these financial statements. 



**Oracle Head & Neck Cancer UK Cash flow statement YEAR ENDED 31 MAY 2024** 

**2024** 

**2023** 


**----- Start of picture text -----**<br>
£ £ £ £<br>Net cash used in operating activities 39,469 (107,743)<br>Cash inflows from investing activities<br>Investment income 3,474 974<br>Payments to acquire tangible fixed assets (852)<br>Net cash provided by investing activities 3,474 122<br>Net change in cash and cash equivalents 42,943 (107,621)<br>Cash at bank and in hand at start of year 362,664 470,285<br>Cash at bank and in hand at end of year 405,607 362,664<br>Note - reconciliation of net expenditure to net cash flow from operating activities<br>Net income (expenditure) (as per statement of financial activities) 134,793 55,238<br>Investment income (3,474) (974)<br>Depreciation of tangible assets 284 118<br>(Increase) /decrease in debtors (21,505) (7,831)<br>(Decrease) / increase creditors (70,629) (154,294)<br>Net cash used in operating activities 39,469 (107,743)<br>Analysis of cash & cash equivalents<br>Cash in hand 405,607 362,664<br>Total 405,607 362,664<br>**----- End of picture text -----**<br>


46 



**Oracle Head & Neck Cancer UK Notes to the financial statements YEAR ENDED 31 MAY 2024** 

## ACCOUNTING POLICIES 

## a) Accounting convention 

These financial statements are prepared on a going concern basis, under the historical cost convention. The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) including Update Bulletin 1. The Company is a public benefit entity for the purposes of FRS 102 and a registered charity established as a company limited by guarantee and therefore has also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Companies Act 2006. 

Oracle Cancer Trust meets the definition of a public benefit entity under FRS 102. 

The financial statements have been prepared in sterling, which is the functional currency of the entity. Monetary amounts in these financial statements are rounded to the nearest pound. 

## b) Going concern 

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the charitable group to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. In particular the trustees have considered the charitable company’s forecasts and projections and have taken account of pressures on donation and investment income. After making enquiries the trustees have concluded that there is a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. The charitable company therefore continues to adopt the going concern basis in preparing its financial statements. At the date of sign off, the Trustees confirm there are no material uncertainties in relation to the going concern assumption. 

## Incoming resources 

## c) 

All incoming resources are included in the Statement of Financial Activities when the charity is entitled to the income, the receipts is probable and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income: 

Legacies are recognised following probate and once there is sufficient evidence that receipt is probable and the amount of the legacy receivable can be measured reliability. Where entitlement to a legacy exits but there is uncertainty as to its receipt or the amount receivable, details are disclosed as a contingent asset until the criteria for income recognition are met. 

Bank interest is accounted for on an accruals basis. 

Voluntary income by way of donations and gifts is included in full in the Statement of 

Financial Activities when receivable. 

## d) Resources expended and irrecoverable VAT 

Resources expended including grants are included in the Statement of Financial Activities on an accruals basis. Commitment to fund future grants are recognised as liabilities once the obligation has been communicated to the grant recipient. Where there is an annual review or other performance review related conditions which means that te charity may withdraw a commitment if the conditions are not met, the liability is not recognised until the conditions have been fulfiled, and the commitment can no longer be revoked. 

Expenditure includes VAT which is not recoverable by the charity. The majority of costs are attributable to specific charitable activities. Support costs include central functions and are allocated to cost categories on the basis of staff time spent on those cost categories. Governance costs include those costs associated with meeting the constitutional and Statutory requirements of the charity. 

## e) Allocation of support costs 

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the Trusts artistic programmes and activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities. Further detail can be found in Note 5. 

## f) 

## Operating leases 

The charity classifies the leasing of office equipment as operating leases, the title remains with the lessor. Rental charges are charged on a straight line basis over the lease period. 

## g) Tax status 

Oracle Cancer Trust has suffered no tax charge, as it is not subject to UK Corporation tax on its charitable activities. 

## h) Fund Accounting 

Funds held by the charity are either: Unrestricted general funds - these are funds that can be used in accordance with the charitable objectives at the discretion of the trustees. Designated funds - these are funds that are set aside by the trustees out of unrestricted general funds for specific future purposes or projects. Restricted funds - these are funds that are subject to restrictions on their expenditure imposed by the donor. 

## i) Fixed assets 

Depreciation is provided at the following annual estimated useful life. 

Rates in order to write off each asset over its estimated useful life. 

## j) Government grants 

Government Grants represent funding received from the AMRC for qualifying projects. Funds arerecognised on receipt. 

Computer equipment - Straight line over 3 years 

## k) Financial Instruments 

Cash and cash equivalents 

Cash and cash equivalents include cash at banks and in hand and short term deposits with a maturity date of three months or less. 

## Debtors and creditors 

Debtors and creditors receivable or payable within one year of the reporting date are carried at their at transaction price. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest. 

47 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
2024 2023<br>1) DONATIONS<br>£ £<br>General donations restricted 119,473 32,300<br>unrestricted<br>219,605 140,521<br>funds<br>Grant funding restricted 124,793 283,894<br>unrestricted<br>10,500 18,488<br>funds<br>The Trust benefits greatly from the involvement and enthusiastic support of its many volunteers,<br>details of which are given in our annual report. In accordance with FRS 102 and the Charities SORP 474,371 475,203<br>(FRS 102), the economic contribution of general volunteers is not recognised in the accounts.<br>2024 2023<br>2) INVESTMENT INCOME<br>£ £<br>Bank interest receivable - unrestricted funds 3,475 974<br>3,475 974<br>2024 2023<br>3) COSTS OF GENERATING VOLUNTARY INCOME<br>£ £<br>Unrestricted<br>Fundraising Costs Salaries and Fees 99,649 56,257<br>Events 13,448 33,661<br>Support Costs<br>allocated (Note 5) 42,209 68,484<br>155,306 158,402<br>**----- End of picture text -----**<br>


48 



## **Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
2024 2023<br>4) CHARITABLE ACTIVITIES AND GOVERNANCE COSTS<br>£ £<br>Research grants 2,852 172,126<br>Impact delivery Salaries 68,979 -<br>Patient Support 28,133 1,284<br>Events 22,300 -<br>Website 5,631 -<br>Lecturer fees & expenses 23,232 495<br>Support costs (Note 5) 9,601 65,785<br>Governance costs (Note 6) 48,071 46,918<br>208,799 286,608<br>All grants are payable to a range of research organisations to cover salaries and expenses of researchers. During 2024 the charity was paying grants accrued in prior years.<br>**----- End of picture text -----**<br>


49 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
2024 2023<br>5) SUPPORT COSTS<br>£ £<br>Sub-contractors 25,084 82,672<br>PR consultancy 7,456 9,277<br>Printing, postage, stationery and database 12,160 11,069<br>Other office, travel and sundry 8,771 21,827<br>Recruitment - 15,000<br>Allocated to Charitable activities (Note 4) (9,601) (65,785)<br>Allocated to Governance costs (Note 6) (1,661) (5,576)<br>42,209 68,484<br>Sub-contractors includes the Chief Executive and Operations Manager.<br>The Trust identifies its support costs, it then identifies those costs relating to Governance. The remaining<br>support costs are allocated between Cost of Generating Funds and Governance. Staff and related costs are<br>allocated on a time basis, overheads are allocated in proportion to staff time.<br>2024 2023<br>6) GOVERNANCE COSTS<br>£ £<br>Bookkeeping  and external audit 27,181 26,665<br>Legal and other professional 19,229 14,677<br>Support costs allocated (Note 5) 1,661 5,576<br>48,071 46,918<br>**----- End of picture text -----**<br>


50 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
2024 2023<br>7) NET EXPENDITURE FOR THE YEAR<br>£ £<br>This is stated after charging (net of VAT):<br>Fees payable to the Auditor - audit services 5,250 5,000<br>Depreciation charge for the year 284 118<br>5,534 5,118<br>The above figures exclude VAT in accordance with the accounting reporting requirements. The actual cost to<br>the charity was £6,300 (2023 : £6,000)<br>2024 2023<br>8) PERSONNEL<br>£ £<br>Salaries                         159,986                        54,197<br>Employer NI                            12,512                               694<br>Pension costs                               3,167                           1,342<br>Total employment costs                         175,665                        56,233<br>The number of higher paid staff within the following scales were: 2024 2023<br>£60,000 - £69,999 2 -<br>During the year the average numbers of employees was 4 (2023 : 2)<br>The key management personnel of the charity comprise the trustees, the CEO and the fundraising manager. The<br>total compensation paid to key management personnel amounted to £129,999 (2023 : £74,600)<br>**----- End of picture text -----**<br>


51 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
2024<br>9) TANGIBLE FIXED ASSETS<br>£<br>Computer equiptment<br> Cost or Valuation<br> At 31 May 2023  852<br> Additions  -<br>-<br> Disposals<br> At 31 May 2024  852<br> Depreciation<br> At 31 May 2023  118<br> Charge for the year  284<br> Eliminated  -<br> At 31 May 2024  402<br> Net Book Value<br> At 31 May 2024  450<br> At 31 May 2023  734<br>**----- End of picture text -----**<br>


52 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
2024 2023<br>10) Debtors<br>£ £<br>Grant and event debtors 5,000 5,000<br>Other debtors and prepayments 30,000 8,496<br>35,000 13,496<br>2024 2023<br>11) CREDITORS - Due within 1 year<br>£ £<br>Grant accruals 80,076 163,313<br>Deferred Income and other accruals 7,215 11,760<br>Trade creditors 33,092 2,400<br>Social security and other taxes 3,786 2,321<br>Other creditors 850 336<br>125,019 180,130<br>2024 2023<br>12) CREDITORS - Due after 1 year<br>£ £<br>Grant accruals - 15,519<br>-<br>15,519<br>**----- End of picture text -----**<br>


53 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
Balance  Balance<br>Income Expenditure Transfers<br>13) Restricted Funds 1 June 2023 £ £ £ 31 May 2024<br>£ £<br>- - -<br>CHK/AMRC/Mason Le Page/Get-a-head for Koteva 30,000 (30,000)<br>AMRC & Swire - Pioneers of Discovery - supporting Fleming and Melake 16,998 48,965 (15,340) (49,167) 1,456<br>AMRC for Lin 16,814 - (239) - 16,575<br>- - -<br>University of Southampton - Lola internship 1,100 (1,100)<br>AMRC for Marsh - 34,078 (9) (34,069) -<br>HPV awareness - 6,750 - - 6,750<br>- - -<br>PPI projects 53,904 53,904<br>- - -<br>Young Tongues 10,569 (10,569)<br>- - -<br>Late Effects project 5,000 5,000<br>- - -<br>Inequalities project 25,000 (25,000)<br>- - -<br>Oncology meeting, York - Merck 30,000 30,000<br>- - -<br>Mercers Livery 1,850 1,850<br>36,762 244,266 (27,257) (138,236) 115,535<br>**----- End of picture text -----**<br>


54 




**----- Start of picture text -----**<br>
Oracle Head & Neck Cancer UK<br>NOTES TO THE FINANCIAL STATEMENTS (continued) Balance  Balance<br>Income Expenditure Transfers<br>YEAR ENDED 31 MAY 2024 1 June 2022 31 May 2023<br>£ £ £<br>£ £<br>13) Restricted Funds<br>-<br>CHK/AMRC / Mason Le Page for Koteva 12,033 38,076 (37,500) (12,609)<br>AMRC & Swire - Pioneers of Discovery - supporting Fleming and Melake 52,662 44,489 (68,179) (11,974) 16,998<br>AMRC for Emmanuel Patin 31,520 104,208 (13,068) (122,660) -<br>Beaumont/Terradace for Marsh 34,079 - - (34,079) -<br>AMRC for Lin 30,824 - (14,010) - 16,814<br>AMRC for Cicero / Sala - 57,500 (57,500) -<br>AMRC for Freckleton - 18,488 (34,278) 15,790 -<br>AMRC for Chan - 26,133 (22,725) (3,408) -<br>- -<br>University of Southampton - Lola internship 2,300 (1,200) 1,100<br>- -<br>Inequalities project 25,000 (62,076) 37,076<br>- - -<br>Mercers Livery 1,850 1,850<br>Pennycress Trust 200 - - (200) -<br>Additional details: 163,168 316,194 (253,036) (189,564) 36,762<br>**----- End of picture text -----**<br>


AMRC 2023 funding of £283,894 was received and allocated to the following projects Koteva - 4 year project to research the development of daily automated treatment adaptation for MRI guided radio-therapy of head and neck cancer patients. Brunel - This research is investigating the role of a gene, MYB, that is frequently altered in ACC and thought to be a cause of radio and chemo-resistance. Melake - Research looking at using immunoproteomics to identify molecular markers of tumour cell sensitivity and resistance to killing by cytotoxic T cell, the effectors of anti-tumour immunity. University of Derby - Research to study the life cycle of HPV infections to determine how they can lead to head & neck cancers. 

Patin - 4 year research study to look at the modulation of the immune tumour micro-environment by combinations of radiotherapy and DNA damage response-targeted drugs. 

Chan - Research to study the dynamics of T-cell-driven immune responses to radiotherapy and immunotherapy in a HPV16- positive model of Head and Neck Squamous Cell Carcinoma. 

The CHK fund is currently supporting PhD student, Jennifer Kieselmann, to undertake a cutting-edge computational project at the ICR’s Division of Radiotherapy and Imaging. Jennifer is designing software that will allow clinicians to automatically define the boundaries between normal tissues and cancerous tumours on MRI images. It is hoped that Jennifer’s work will help to support the development of real-time adaptive radiation therapies such as those that will be delivered by the Royal Marsden Hospital’s revolutionary new MR Linac machine. 

The Swire/Adrian Swire Charitable trust is funding towards the establishment of a dedicated thyroid cancer research group at the ICR. Thyroid cancers are the most common endocrine tumours and one of the three most prevalent head and neck cancer types in women. The group that has been established is looking to find specific combinations of drugs that will provide a more effective treatment for patients currently exhibiting the treatment-resistant form of the disease. 

55 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
Balance 1<br>14) UNRESTRITED FUNDS June 2023  Income Expenditure Transfers Balance 31 May 2024<br>£ £ £ £ £<br>Designated funds<br>Blair Hesketh Memorial   64,793  - (4,320) - 60,473<br>General unrestricted funds 79,690            254,632  (332,528) 138,236 140,030<br>144,483           254,632  (336,848) 138,236 200,503<br>Balance 1<br>Income Expenditure Transfers Balance 31 May 2023<br>June 2022<br>£ £ £ £<br>£<br>Designated funds<br>Blair Hesketh Memorial                66,293  - (1,500) - 64,793<br>General unrestricted funds (103,454)           184,055  (190,475) 189,564  79,690<br>(37,161)           184,055  (191,975) 189,564  144,483<br>The Blair Hesketh Memorial Fund has been set up to provide funds for the Blair Hesketh lectures.<br>15) TRUSTEES REMUNERATION AND EXPENSES<br>No trustee received any remuneration or reimbursement for expenses in respect of the current year or proceeding period.<br>16) RELATED PARTY TRANSACTIONS<br>Three medical Trustee Directors sit on the Research Sub-Committee. Consequently they make recommendations upon the direction of the research, allocation of funding and  related appointments. There is potential<br>for indirect benefit to accrue to these medical Trustee Directors, for example, where the funded appointee delivers a partial clinical role which may alleviate their own clinical responsibilities. To mitigate this risk of<br>related party benefit, the Research Sub-Committee is chaired by an independent Non Executive Director and it formally passes any funding proposals to the Finance & Investment Sub-Committee (whose members are<br>non-medical) for review and necessary approval before onwards submission for a final Board decision.<br>Disclosures relating to Key Management Personnel are detailed in Note 8<br>**----- End of picture text -----**<br>


56 



**Oracle Head & Neck Cancer UK NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MAY 2024** 


**----- Start of picture text -----**<br>
Unrestricted Designated Restricted 2024 Total<br>17) ANALYSIS OF NET ASSETS BETWEEN FUNDS<br>£ £ £ £<br>Tangible fixed assets 450 - - 450<br>Debtors - - 35,000 35,000<br>Cash at bank and in hand 245,023 60,473 100,111 405,607<br>-<br>Creditors due within one year (105,443) (19,576) (125,019)<br>Balance on fund 140,030 60,473 115,535 316,038<br>18) CONTROL<br>The Charity is controlled by the Trustees under the terms of the Trust Deed.<br>**----- End of picture text -----**<br>


57 



J)
Nll
MACHAI, G E
ELEVATION.. 1È004
Tt6ETATIONE ZOME: ¥DMIA
FORE
FROII IIACHAME CATE TO:
MAGHaHE CAMI. IIKII j SHR
.SHIRA CAVE CAMP. IGIIM I iiiiRs )
LAVI4 YtsIIER: 11511RS)
. ARROH GLACIER: 25KM (IG.30HR8)
BARANCO: Z 'Y.¥ i i7HRSI
• KARANCA.. (ZIHRS)
4 BAPAFU CAMP:_
JKII (25HR51
14tiuiiu r
7¥14
XR¢!
t•
3d&
Can

**At Oracle Head & Neck Cancer UK, we're working towards a world where head and neck cancer no longer devastates lives. We support those affected by head and neck cancer today, fund pioneering research for better treatments tomorrow, and raise vital awareness to promote earlier diagnosis.** 

**Call us** 0203 475 3471 

**Email us** info@oraclehnc.org.uk 

**Visit us** oraclehnc.org.uk 

## **Write to us** 

85 Great Portland Street First Floor London W1W 7LT 

## **Follow us** 

@oraclehncuk 





Oracle Head & Neck Cancer UK is a registered charity in England and Wales (1142037), and in Scotland (SC052790). Registered as a company limited by guarantee in England and Wales (7125497). Registered address: 80 Coombe Road, New Malden KT3 4QS. 



61